{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:26:13Z","timestamp":1792070773984,"version":"4.4.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13300-025-01829-1","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:25:46Z","timestamp":1767594346000},"page":"317-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2247-9679","authenticated-orcid":false,"given":"Jos\u00e9 Pablo","family":"Miramontes-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Rodrigo-Ala\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Gabella-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Carretero-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Corral-Gudino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"1829_CR1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2021","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF; 2021.","edition":"10"},{"key":"1829_CR2","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2337\/dc17-1962","volume":"41","author":"C Bommer","year":"2018","unstructured":"Bommer C, Heesemann E, Sagalova V, et al. The global economic burden of diabetes. Diabetes Care. 2018;41:963\u201370.","journal-title":"Diabetes Care"},{"key":"1829_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, et al. Risk factors, mortality, and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;379:633\u201344.","journal-title":"N Engl J Med"},{"key":"1829_CR4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and mortality in type 2 diabetes. J Am Soc Nephrol. 2013;24:302\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1829_CR5","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","volume":"380","author":"CS Fox","year":"2012","unstructured":"Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease with major outcomes. Lancet. 2012;380:1662\u201373.","journal-title":"Lancet"},{"key":"1829_CR6","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560\u201372.","journal-title":"N Engl J Med"},{"key":"1829_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of GLP-1. Cell Metab. 2018;27:740\u201356.","journal-title":"Cell Metab"},{"key":"1829_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"1829_CR9","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"1829_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019;394:121\u201330.","journal-title":"Lancet"},{"key":"1829_CR11","first-page":"361","volume":"133","author":"AJ Scheen","year":"2019","unstructured":"Scheen AJ. Cardiovascular effects of DPP-4 inhibitors and their interactions with the kidney. Clin Sci (Lond). 2019;133:361\u201378.","journal-title":"Clin Sci (Lond)"},{"key":"1829_CR12","first-page":"1015","volume":"41","author":"JJ Holst","year":"2020","unstructured":"Holst JJ, Deacon CF. Glucagon-like peptide-1 physiology and pharmacology. Endocr Rev. 2020;41:1015\u201368.","journal-title":"Endocr Rev"},{"issue":"S1","key":"1829_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(S1):5\u201321.","journal-title":"Diabetes Obes Metab"},{"key":"1829_CR14","first-page":"1013","volume":"70","author":"A Basu","year":"2017","unstructured":"Basu A, Charkoudian N, Schrage W, et al. Vascular actions of GLP-1. Hypertension. 2017;70:1013\u201322.","journal-title":"Hypertension"},{"key":"1829_CR15","first-page":"F373","volume":"320","author":"SC Thomson","year":"2021","unstructured":"Thomson SC, Kashkouli A, Singh P. A kidney perspective on GLP-1 receptor agonists. Am J Physiol Renal Physiol. 2021;320:F373\u201385.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1829_CR16","first-page":"466","volume":"98","author":"T Matsui","year":"2020","unstructured":"Matsui T, Nishino Y, Takeuchi M, et al. GLP-1 improves renal microvascular function via PI3K-Akt-eNOS. Kidney Int. 2020;98:466\u201378.","journal-title":"Kidney Int"},{"key":"1829_CR17","doi-asserted-by":"crossref","first-page":"101470","DOI":"10.1016\/j.redox.2020.101470","volume":"32","author":"WJ Liu","year":"2020","unstructured":"Liu WJ, Zhang H, Xu H, et al. GLP-1 analogs activate Nrf2 to protect podocytes. Redox Biol. 2020;32:101470.","journal-title":"Redox Biol"},{"key":"1829_CR18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2337\/db19-2018-P","volume":"68","author":"F Zeng","year":"2019","unstructured":"Zeng F, Lau W, Deng S, et al. Liraglutide suppresses renal fibrosis via TGF-\u03b2\/Smad3 inhibition. Diabetes. 2019;68:324\u201335.","journal-title":"Diabetes"},{"issue":"1","key":"1829_CR19","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1038\/s41467-023-41893-4","volume":"14","author":"SC Wright","year":"2023","unstructured":"Wright SC, Motso A, Koutsilieri S, Beusch CM, Sabatier P, Berghella A, et al. GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics. Nat Commun. 2023;14(1):6243. https:\/\/doi.org\/10.1038\/s41467-023-41893-4. (PMID:37813859; PMCID:PMC10562414).","journal-title":"Nat Commun"},{"issue":"24","key":"1829_CR20","doi-asserted-by":"publisher","first-page":"7732","DOI":"10.3390\/jcm13247732","volume":"13","author":"AM Abdelrahman","year":"2024","unstructured":"Abdelrahman AM, Awad AS, Hasan I, Abdel-Rahman EM. Glucagon-like peptide-1 receptor agonists and diabetic kidney disease: from bench to bed-side. J Clin Med. 2024;13(24):7732. https:\/\/doi.org\/10.3390\/jcm13247732. (PMID:39768655; PMCID:PMC11677827.23).","journal-title":"J Clin Med"},{"issue":"3","key":"1829_CR21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3390\/biomedicines12030657","volume":"12","author":"M Rroji","year":"2024","unstructured":"Rroji M, et al. The molecular pathways through which GLP1-RAs impact the kidney: from bench to bedside. Biomedicines. 2024;12(3):657. https:\/\/doi.org\/10.3390\/biomedicines12030657.","journal-title":"Biomedicines"},{"key":"1829_CR22","doi-asserted-by":"publisher","first-page":"204201882312223","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222370. https:\/\/doi.org\/10.1177\/20420188231222367.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"1829_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/ATVBAHA.119.313034","volume":"40","author":"J Helmst\u00e4dter","year":"2020","unstructured":"Helmst\u00e4dter J, et al. Endothelial GLP-1 receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscler Thromb Vasc Biol. 2020;40(1):145\u201358. https:\/\/doi.org\/10.1161\/ATVBAHA.119.313034.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"1829_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bph.15497","volume":"179","author":"B Jones","year":"2022","unstructured":"Jones B. The therapeutic potential of GLP-1 receptor-biased agonism. Br J Pharmacol. 2022;179(4):492\u2013510. https:\/\/doi.org\/10.1111\/bph.15497. (Epub 2021 May 20. PMID: 33880754; PMCID: PMC8820210.).","journal-title":"Br J Pharmacol."},{"issue":"12","key":"1829_CR25","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1172\/JCI140046","volume":"130","author":"OS Oduori","year":"2020","unstructured":"Oduori OS, Murao N, Shimomura K, Takahashi H, Zhang Q, Dou H, et al. Gs\/Gq signaling switch in \u03b2 cells defines incretin effectiveness in diabetes. J Clin Invest. 2020;130(12):6639\u201355. https:\/\/doi.org\/10.1172\/JCI140046. (PMID:33196462;PMCID:PMC7685756).","journal-title":"J Clin Invest"},{"issue":"10","key":"1829_CR26","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.3390\/biomedicines10102586","volume":"10","author":"T Bulum","year":"2022","unstructured":"Bulum T. Nephroprotective properties of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. Biomedicines. 2022;10(10):2586. https:\/\/doi.org\/10.3390\/biomedicines10102586. (PMID:36289848;PMCID:PMC9599125).","journal-title":"Biomedicines"},{"key":"1829_CR27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40262-014-0217-3","volume":"54","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Clinical pharmacokinetics of DPP-4 inhibitors. Clin Pharmacokinet. 2015;54:319\u201332.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1829_CR28","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ki.2013.427","volume":"85","author":"H Fujita","year":"2014","unstructured":"Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, Hosoba M, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int. 2014;85(3):579\u201389. https:\/\/doi.org\/10.1038\/ki.2013.427.","journal-title":"Kidney Int"},{"key":"1829_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes. N Engl J Med. 2021;385:503\u201315.","journal-title":"N Engl J Med"},{"key":"1829_CR30","first-page":"1114","volume":"377","author":"M Bossart","year":"2022","unstructured":"Bossart M, Wagner M, Elvert R, et al. Triple-hormone receptor agonists for obesity and type 2 diabetes. Science. 2022;377:1114\u201321.","journal-title":"Science"},{"key":"1829_CR31","first-page":"919","volume":"129","author":"DZI Cherney","year":"2014","unstructured":"Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of combining GLP-1RA and SGLT2 inhibition. Circulation. 2014;129:919\u201331.","journal-title":"Circulation"},{"issue":"10400","key":"1829_CR32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(23)01302-8.","journal-title":"Lancet"},{"issue":"10","key":"1829_CR33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity: a randomised, controlled, phase 2 trial. N Engl J Med. 2023;389(10):877\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2302392.","journal-title":"N Engl J Med"},{"key":"1829_CR34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505669","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Hsia S, Nevarez LN, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes (ACHIEVE-1). N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2505669.","journal-title":"N Engl J Med"},{"key":"1829_CR35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774","author":"S Wharton","year":"2025","unstructured":"Wharton S, Aronne LJ, Stefanski A, et al. ATTAIN-1 trial investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2511774.","journal-title":"N Engl J Med"},{"issue":"10","key":"1829_CR36","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2302392. (GZGI Investigators).","journal-title":"N Engl J Med"},{"key":"1829_CR37","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, \u00d8rsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839\u201348.","journal-title":"N Engl J Med"},{"key":"1829_CR38","first-page":"1691","volume":"41","author":"T Vilsb\u00f8ll","year":"2018","unstructured":"Vilsb\u00f8ll T, Bain SC, Leiter LA, et al. Semaglutide and diabetic retinopathy in SUSTAIN-6. Diabetes Care. 2018;41:1691\u20138.","journal-title":"Diabetes Care"},{"issue":"10","key":"1829_CR39","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1829_CR40","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/dc25-0241","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee MMY, Sattar N, Pop-Busui R, Deanfield J, Emerson SS, Inzucchi SE, et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care. 2025;48(5):846\u201359. https:\/\/doi.org\/10.2337\/dc25-0241. (SOUL Trial Investigators).","journal-title":"Diabetes Care"},{"key":"1829_CR41","first-page":"190","volume":"10","author":"SL Kristensen","year":"2022","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al. Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2022;10:190\u2013200.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"20","key":"1829_CR42","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2501006. (SOUL Study Group).","journal-title":"N Engl J Med"},{"key":"1829_CR43","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ejhf.2578","volume":"24","author":"F Zannad","year":"2022","unstructured":"Zannad F, Butler J, Filippatos G, et al. Rationale and design of the SOUL trial: semaglutide in heart failure with reduced ejection fraction and type 2 diabetes. Eur J Heart Fail. 2022;24:807\u201317.","journal-title":"Eur J Heart Fail"},{"issue":"10437","key":"1829_CR44","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","volume":"403","author":"J Butler","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstr\u00f8m SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437):1635\u201348.","journal-title":"Lancet"},{"issue":"15","key":"1829_CR45","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure with type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407.","journal-title":"N Engl J Med"},{"issue":"5","key":"1829_CR46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Latkovskis G, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"16","key":"1829_CR47","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMc2502743","volume":"392","author":"J Wagner","year":"2025","unstructured":"Wagner J. Tirzepatide for heart failure and obesity. N Engl J Med. 2025;392(16):1659\u201360.","journal-title":"N Engl J Med"},{"key":"1829_CR48","unstructured":"Eli Lilly and Company. A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial. ClinicalTrials.gov Identifier: NCT04847557. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04847557"},{"key":"1829_CR49","first-page":"603","volume":"38","author":"DZI Cherney","year":"2023","unstructured":"Cherney DZI, Heerspink HJL, Zinman B, et al. Design and baseline characteristics of FLOW: a kidney outcomes trial of semaglutide in type 2 diabetes. Nephrol Dial Transplant. 2023;38:603\u201312.","journal-title":"Nephrol Dial Transplant"},{"key":"1829_CR50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12933-021-01385-5","volume":"20","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Design and rationale of SELECT: semaglutide effects on cardiovascular outcomes in people with obesity. Cardiovasc Diabetol. 2021;20:196.","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"1829_CR51","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563. (SELECT Trial Investigators).","journal-title":"N Engl J Med"},{"key":"1829_CR52","first-page":"31","volume":"250","author":"AF Hernandez","year":"2022","unstructured":"Hernandez AF, Green JB, Janmohamed S, et al. Design of SURPASS-CVOT: cardiovascular outcomes with tirzepatide versus dulaglutide. Am Heart J. 2022;250:31\u201340.","journal-title":"Am Heart J"},{"key":"1829_CR53","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"TD M\u00fcller","year":"2023","unstructured":"M\u00fcller TD, Finan B, Bl\u00fcher M, et al. Retatrutide, a multireceptor agonist, for obesity and type 2 diabetes. N Engl J Med. 2023;389:514\u201326.","journal-title":"N Engl J Med"},{"key":"1829_CR54","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022 consensus report by the ADA and the EASD. Diabetologia. 2022;65:1925\u201366.","journal-title":"Diabetologia"},{"key":"1829_CR55","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO clinical practice guideline for diabetes management in CKD. Kidney Int. 2022;102:S1\u2013127.","journal-title":"Kidney Int"},{"key":"1829_CR56","first-page":"1434","volume":"17","author":"AD Kaze","year":"2022","unstructured":"Kaze AD, Santhanakrishnan K, Erqou S, et al. GLP-1 receptor agonists in advanced CKD and dialysis: a systematic review. Clin J Am Soc Nephrol. 2022;17:1434\u201346.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1829_CR57","first-page":"108319","volume":"250","author":"S Yang","year":"2024","unstructured":"Yang S, Han X, Zheng H, et al. Exosome-mediated renoprotection by GLP-1 analogues: mechanistic insights and therapeutic prospects. Pharmacol Ther. 2024;250:108319.","journal-title":"Pharmacol Ther"},{"key":"1829_CR58","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s13300-023-01411-7","volume":"14","author":"R Pratley","year":"2023","unstructured":"Pratley R, Gilbert MP, Bl\u00fcher M, et al. Cost-effectiveness of tirzepatide for type 2 diabetes in the United States. Diabetes Ther. 2023;14:1037\u201353.","journal-title":"Diabetes Ther"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01829-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01829-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01829-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:22:04Z","timestamp":1773822124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01829-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1829"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01829-1","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors (Jos\u00e9 Pablo Miramontes-Gonz\u00e1lez, \u00c1lvaro Rodrigo-Ala\u00edz, Miriam Gabella-Mart\u00edn, David Gonz\u00e1lez-Calle, Juana Carretero-G\u00f3mez and Luis Corral-Gudino) have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}